Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/02/22
Emergent Biosolutions (EBS) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/01/22
Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health EmergencyInvestorPlace • 07/25/22
Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022GlobeNewsWire • 07/18/22
Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for EbolaGlobeNewsWire • 07/07/22
Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of DirectorsGlobeNewsWire • 07/06/22
Emergent BioSolutions says FDA has accepted its anthrax vaccine candidate for reviewMarket Watch • 06/24/22
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine CandidateGlobeNewsWire • 06/24/22
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious DiseasesGlobeNewsWire • 06/21/22